Contents . 4 Statement of Purpose . 4 Group 3. 5 Structure and Function 3.1 5 Role & Function of the Group 3.2 13-1C-101h 5 Network Configuration 3.3 6 Network Group Members 3.4 7 Local Haemato-oncology Teams 13-1C-102h 7 Network Group Membership 3.6 Group Meetings 13-1C-103h 8 3.7 Work Programme and Annual Report 13-1C-104h 8 4. 8 Coordination of Care/Patient Pathway 4.1 13-1C-105h 8 Investigational Guidelines Applicable to an NSSG hosting a SIHMDS 4.2 Investigational Guidelines Applicable to an NSSG referring cases to a 13-1C-106h 8 SIHMDS in another area 4.3 13-1C-107h 8 Clinical Guidelines 9 4.4 Primary Care Referral Guidelines 4.5i 9 Clinical Guidelines for Leukaemia & Other Myeloid Disorders 4.5ii 9 Clinical Guidelines for Lymphoid Disorders 4.5iii Clinical Guidelines for Plasma Cell Malignancies 9 4.6 Chemotherapy Treatment Algorithms 13-1C-108h 9 4.7 Referral Guidelines for Patients moving between Teams 9 4.8 Clinical Diagnostic Pathways 13-1C-109h 9 e 4.9 13-1C-110h 9 Patient Pathways (inc TYANC pathways) 5. 13-1C-111h 9 Patient Experience 6. 9 Clinical Outcomes/Indicators 6.1 13-1C-112h 9 Clinical Outcomes Indicators and Audits 6.2 13-1C-113h 9 Discussion of Clinical Trials 7. Data Collection 9 7.1 9 Network-wide Minimum Data Set 8. 10 Distribution of Guidelines & Protocols 9. App 1 11 Terms of Reference
Contents . Statement of Purpose 4 . Group 4 3. Structure and Function 5 3.1 Role & Function of the Group 5 3.2 Network Configuration 13-1C-101h 5 3.3 Network Group Members 6 3.4 Local Haemato-oncology Teams 7 Network Group Membership 13-1C-102h 7 3.6 Group Meetings 13-1C-103h 8 3.7 Work Programme and Annual Report 13-1C-104h 8 4. Coordination of Care/Patient Pathway 8 4.1 Investigational Guidelines Applicable to an NSSG hosting a SIHMDS 13-1C-105h 8 4.2 Investigational Guidelines Applicable to an NSSG referring cases to a SIHMDS in another area 13-1C-106h 8 4.3 Clinical Guidelines 13-1C-107h 8 4.4 Primary Care Referral Guidelines 9 4.5i Clinical Guidelines for Leukaemia & Other Myeloid Disorders 9 4.5ii Clinical Guidelines for Lymphoid Disorders 9 4.5iii Clinical Guidelines for Plasma Cell Malignancies 9 4.6 Chemotherapy Treatment Algorithms 13-1C-108h 9 4.7 Referral Guidelines for Patients moving between Teams e 9 4.8 Clinical Diagnostic Pathways 13-1C-109h 9 4.9 Patient Pathways (inc TYANC pathways) 13-1C-110h 9 5. Patient Experience 13-1C-111h 9 6. Clinical Outcomes/Indicators 9 6.1 Clinical Outcomes Indicators and Audits 13-1C-112h 9 6.2 Discussion of Clinical Trials 13-1C-113h 9 7. Data Collection 9 7.1 Network-wide Minimum Data Set 9 8. Distribution of Guidelines & Protocols 10 9. App 1 Terms of Reference 11
Haematology-NSSG-Constitution-Approved-15.10.15.docx